- Home
- ALXO vs XBP Comparison
ALXO vs XBP Comparison
Compare ALXO & XBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALXO
- XBP
- Stock Information
- Founded
- ALXO 2015
- XBP 2020
- Country
- ALXO United States
- XBP United States
- Employees
- ALXO N/A
- XBP N/A
- Industry
- ALXO Biotechnology: Pharmaceutical Preparations
- XBP Business Services
- Sector
- ALXO Health Care
- XBP Consumer Discretionary
- Exchange
- ALXO Nasdaq
- XBP Nasdaq
- Market Cap
- ALXO 79.7M
- XBP 69.1M
- IPO Year
- ALXO 2020
- XBP N/A
- Fundamental
- Price
- ALXO $1.47
- XBP $0.65
- Analyst Decision
- ALXO Strong Buy
- XBP
- Analyst Count
- ALXO 6
- XBP 0
- Target Price
- ALXO $3.30
- XBP N/A
- AVG Volume (30 Days)
- ALXO 356.5K
- XBP 354.0K
- Earning Date
- ALXO 11-07-2025
- XBP 11-14-2025
- Dividend Yield
- ALXO N/A
- XBP N/A
- EPS Growth
- ALXO N/A
- XBP N/A
- EPS
- ALXO N/A
- XBP N/A
- Revenue
- ALXO N/A
- XBP $62,823,000.00
- Revenue This Year
- ALXO N/A
- XBP N/A
- Revenue Next Year
- ALXO N/A
- XBP N/A
- P/E Ratio
- ALXO N/A
- XBP N/A
- Revenue Growth
- ALXO N/A
- XBP N/A
- 52 Week Low
- ALXO $0.40
- XBP $0.42
- 52 Week High
- ALXO $2.27
- XBP $2.56
- Technical
- Relative Strength Index (RSI)
- ALXO 49.39
- XBP 54.37
- Support Level
- ALXO $1.29
- XBP $0.55
- Resistance Level
- ALXO $1.56
- XBP $0.73
- Average True Range (ATR)
- ALXO 0.18
- XBP 0.07
- MACD
- ALXO 0.01
- XBP 0.01
- Stochastic Oscillator
- ALXO 65.90
- XBP 71.42
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About XBP XBP Europe Holdings Inc.
XBP Global Holdings Inc is a multinational leader in business process automation, serving over 2,500 clients-including more than 30 Fortune 100 companies. Its proprietary software and deep domain expertise position it as a trusted technology and services partner. With cloud-based solutions and a global footprint, XBP Global delivers measurable value, improves advances digital transformation, improves market-wide liquidity by expediting payments, and promotes sustainable business practices.